 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Panbela Therapeutics issued new patent in China for SBP-101 production process

Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive...

Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of...

Panbela to Present at the LD Micro Investor Conference

Patent developed in collaboration with SanofiMINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing...

Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi

Panbela Therapeutics, Inc. (NASDAQ:PBLA  Get Free Report)s stock price rose 2.2% during trading on Friday . The stock traded as high as $1.47 and last traded at $1.42. Approximately...

Panbela Therapeutics (NASDAQ:PBLA) Stock Price Up 2.2%

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc.(Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. ...

Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, ...

Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101

Panbela Therapeutics, Inc. (PBLA) Q2 2023 Earnings Call Transcript

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent...

Panbela Provides Business Update and Reports Q2 2023 Financial Results

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- PanbelaTherapeutics,Inc.(Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern...

Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Watchers	4,242
52-Wk Low	$1.21
52-Wk High	$384.00

Market Cap	$3.87M
Volume (M)	15,397.00
52-Wk High	$384.00
52-Wk Low	$1.21

PBLA Panbela Therapeutics Inc

About

Feed

News

Earnings

Fundamentals